nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—head and neck cancer	0.31	0.636	CbGaD
Gefitinib—CYP1A1—head and neck cancer	0.177	0.364	CbGaD
Gefitinib—EGFR—Docetaxel—head and neck cancer	0.141	0.46	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—head and neck cancer	0.0306	0.0995	CbGbCtD
Gefitinib—CYP2D6—Hydroxyurea—head and neck cancer	0.0272	0.0885	CbGbCtD
Gefitinib—ABCG2—Docetaxel—head and neck cancer	0.0234	0.076	CbGbCtD
Gefitinib—ALB—Fluorouracil—head and neck cancer	0.0211	0.0686	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—head and neck cancer	0.0129	0.0421	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—head and neck cancer	0.0114	0.037	CbGbCtD
Gefitinib—ABCB1—Vinblastine—head and neck cancer	0.0102	0.0332	CbGbCtD
Gefitinib—CYP2D6—Vinblastine—head and neck cancer	0.00963	0.0313	CbGbCtD
Gefitinib—ABCB1—Docetaxel—head and neck cancer	0.00842	0.0274	CbGbCtD
Gefitinib—CYP3A4—Vinblastine—head and neck cancer	0.00612	0.0199	CbGbCtD
Gefitinib—Cancer pain—Docetaxel—head and neck cancer	0.00609	0.0969	CcSEcCtD
Gefitinib—CYP3A4—Docetaxel—head and neck cancer	0.00505	0.0164	CbGbCtD
Gefitinib—Ischaemia—Vinblastine—head and neck cancer	0.00254	0.0404	CcSEcCtD
Gefitinib—ORM1—saliva—head and neck cancer	0.00175	0.0414	CbGeAlD
Gefitinib—Gastrointestinal perforation—Docetaxel—head and neck cancer	0.00168	0.0267	CcSEcCtD
Gefitinib—ERBB3—exocrine gland—head and neck cancer	0.00158	0.0373	CbGeAlD
Gefitinib—ERBB3—hair follicle—head and neck cancer	0.0015	0.0356	CbGeAlD
Gefitinib—MKNK2—hair follicle—head and neck cancer	0.00143	0.0338	CbGeAlD
Gefitinib—IRAK1—hair follicle—head and neck cancer	0.00143	0.0338	CbGeAlD
Gefitinib—Lapatinib—EGFR—head and neck cancer	0.00142	0.284	CrCbGaD
Gefitinib—MKNK1—hair follicle—head and neck cancer	0.00141	0.0334	CbGeAlD
Gefitinib—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.0014	0.0223	CcSEcCtD
Gefitinib—Eruption—Hydroxyurea—head and neck cancer	0.00137	0.0218	CcSEcCtD
Gefitinib—Blepharitis—Hydroxyurea—head and neck cancer	0.00137	0.0218	CcSEcCtD
Gefitinib—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00133	0.0212	CcSEcCtD
Gefitinib—ERBB3—mouth—head and neck cancer	0.00118	0.0279	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinblastine—head and neck cancer	0.00105	0.317	CbGdCrCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—head and neck cancer	0.00103	0.311	CbGdCrCtD
Gefitinib—Febrile neutropenia—Fluorouracil—head and neck cancer	0.00101	0.0161	CcSEcCtD
Gefitinib—Afatinib—EGFR—head and neck cancer	0.00101	0.201	CrCbGaD
Gefitinib—Blepharitis—Fluorouracil—head and neck cancer	0.000987	0.0157	CcSEcCtD
Gefitinib—Tenderness—Hydroxyurea—head and neck cancer	0.000967	0.0154	CcSEcCtD
Gefitinib—Nail disorder—Fluorouracil—head and neck cancer	0.000936	0.0149	CcSEcCtD
Gefitinib—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000907	0.0144	CcSEcCtD
Gefitinib—SBK1—thyroid gland—head and neck cancer	0.0009	0.0213	CbGeAlD
Gefitinib—Ulcer—Hydroxyurea—head and neck cancer	0.000892	0.0142	CcSEcCtD
Gefitinib—CSNK1E—parotid gland—head and neck cancer	0.00085	0.0201	CbGeAlD
Gefitinib—IRAK4—parotid gland—head and neck cancer	0.000837	0.0198	CbGeAlD
Gefitinib—CSNK1E—saliva-secreting gland—head and neck cancer	0.000814	0.0193	CbGeAlD
Gefitinib—IRAK4—saliva-secreting gland—head and neck cancer	0.000802	0.019	CbGeAlD
Gefitinib—SBK1—head—head and neck cancer	0.000798	0.0189	CbGeAlD
Gefitinib—ERBB3—saliva-secreting gland—head and neck cancer	0.000786	0.0186	CbGeAlD
Gefitinib—CHEK2—thyroid gland—head and neck cancer	0.000784	0.0186	CbGeAlD
Gefitinib—MKNK2—parotid gland—head and neck cancer	0.00078	0.0185	CbGeAlD
Gefitinib—MKNK2—saliva-secreting gland—head and neck cancer	0.000747	0.0177	CbGeAlD
Gefitinib—Febrile neutropenia—Docetaxel—head and neck cancer	0.000729	0.0116	CcSEcCtD
Gefitinib—ERBB3—connective tissue—head and neck cancer	0.000722	0.0171	CbGeAlD
Gefitinib—Eruption—Docetaxel—head and neck cancer	0.000713	0.0113	CcSEcCtD
Gefitinib—Erlotinib—EGFR—head and neck cancer	0.00071	0.142	CrCbGaD
Gefitinib—Tenderness—Fluorouracil—head and neck cancer	0.000696	0.0111	CcSEcCtD
Gefitinib—MKNK2—connective tissue—head and neck cancer	0.000687	0.0163	CbGeAlD
Gefitinib—ERBB3—epithelium—head and neck cancer	0.000685	0.0162	CbGeAlD
Gefitinib—Hepatic failure—Hydroxyurea—head and neck cancer	0.000682	0.0109	CcSEcCtD
Gefitinib—Nail disorder—Docetaxel—head and neck cancer	0.000676	0.0108	CcSEcCtD
Gefitinib—CHEK2—Vinorelbine—Vinblastine—head and neck cancer	0.000665	0.2	CbGdCrCtD
Gefitinib—MKNK2—epithelium—head and neck cancer	0.000652	0.0154	CbGeAlD
Gefitinib—Ulcer—Fluorouracil—head and neck cancer	0.000642	0.0102	CcSEcCtD
Gefitinib—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.000641	0.0102	CcSEcCtD
Gefitinib—CSNK1E—trachea—head and neck cancer	0.000628	0.0149	CbGeAlD
Gefitinib—EPHA6—head—head and neck cancer	0.000624	0.0148	CbGeAlD
Gefitinib—Interstitial lung disease—Docetaxel—head and neck cancer	0.000619	0.00986	CcSEcCtD
Gefitinib—IRAK4—trachea—head and neck cancer	0.000618	0.0147	CbGeAlD
Gefitinib—ERBB3—trachea—head and neck cancer	0.000606	0.0144	CbGeAlD
Gefitinib—MKNK2—trachea—head and neck cancer	0.000576	0.0137	CbGeAlD
Gefitinib—Pleural effusion—Docetaxel—head and neck cancer	0.000572	0.00912	CcSEcCtD
Gefitinib—CHEK2—Vincristine—Vinblastine—head and neck cancer	0.000569	0.171	CbGdCrCtD
Gefitinib—MAP3K19—head—head and neck cancer	0.000567	0.0134	CbGeAlD
Gefitinib—MAP2K5—parotid gland—head and neck cancer	0.000566	0.0134	CbGeAlD
Gefitinib—SBK1—lymph node—head and neck cancer	0.000559	0.0132	CbGeAlD
Gefitinib—Vandetanib—VEGFA—head and neck cancer	0.000554	0.111	CrCbGaD
Gefitinib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000543	0.0129	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—head and neck cancer	0.000539	0.0128	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—head and neck cancer	0.000528	0.0125	CbGeAlD
Gefitinib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000519	0.00827	CcSEcCtD
Gefitinib—EGFR—thyroid gland—head and neck cancer	0.000517	0.0122	CbGeAlD
Gefitinib—Thrombophlebitis—Fluorouracil—head and neck cancer	0.000509	0.00811	CcSEcCtD
Gefitinib—MKNK2—lymphoid tissue—head and neck cancer	0.000502	0.0119	CbGeAlD
Gefitinib—CSNK1E—thyroid gland—head and neck cancer	0.000497	0.0118	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—head and neck cancer	0.000496	0.0117	CbGeAlD
Gefitinib—IRAK4—thyroid gland—head and neck cancer	0.000489	0.0116	CbGeAlD
Gefitinib—CHEK2—lymph node—head and neck cancer	0.000487	0.0115	CbGeAlD
Gefitinib—ERBB3—thyroid gland—head and neck cancer	0.000479	0.0114	CbGeAlD
Gefitinib—Drug interaction—Docetaxel—head and neck cancer	0.000473	0.00753	CcSEcCtD
Gefitinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000472	0.00752	CcSEcCtD
Gefitinib—Infestation—Hydroxyurea—head and neck cancer	0.000472	0.00752	CcSEcCtD
Gefitinib—Vandetanib—EGFR—head and neck cancer	0.000468	0.0936	CrCbGaD
Gefitinib—Haemoglobin—Vinblastine—head and neck cancer	0.000467	0.00744	CcSEcCtD
Gefitinib—Haemorrhage—Vinblastine—head and neck cancer	0.000465	0.0074	CcSEcCtD
Gefitinib—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000461	0.00735	CcSEcCtD
Gefitinib—Stomatitis—Hydroxyurea—head and neck cancer	0.00046	0.00733	CcSEcCtD
Gefitinib—MKNK2—thyroid gland—head and neck cancer	0.000456	0.0108	CbGeAlD
Gefitinib—IRAK1—thyroid gland—head and neck cancer	0.000456	0.0108	CbGeAlD
Gefitinib—MKNK1—thyroid gland—head and neck cancer	0.00045	0.0107	CbGeAlD
Gefitinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000446	0.00711	CcSEcCtD
Gefitinib—Respiratory failure—Docetaxel—head and neck cancer	0.000446	0.00711	CcSEcCtD
Gefitinib—CSNK1E—head—head and neck cancer	0.000441	0.0104	CbGeAlD
Gefitinib—Bosutinib—EGFR—head and neck cancer	0.000438	0.0875	CrCbGaD
Gefitinib—IRAK4—head—head and neck cancer	0.000434	0.0103	CbGeAlD
Gefitinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000426	0.00678	CcSEcCtD
Gefitinib—ERBB3—head—head and neck cancer	0.000425	0.0101	CbGeAlD
Gefitinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000424	0.00675	CcSEcCtD
Gefitinib—MAP2K5—trachea—head and neck cancer	0.000418	0.00992	CbGeAlD
Gefitinib—Alopecia—Vinblastine—head and neck cancer	0.000411	0.00654	CcSEcCtD
Gefitinib—STK10—lymphoid tissue—head and neck cancer	0.000408	0.00967	CbGeAlD
Gefitinib—Erlotinib—CYP1A1—head and neck cancer	0.000406	0.0812	CrCbGaD
Gefitinib—MKNK2—head—head and neck cancer	0.000404	0.00958	CbGeAlD
Gefitinib—Dry skin—Fluorouracil—head and neck cancer	0.000404	0.00644	CcSEcCtD
Gefitinib—MKNK1—head—head and neck cancer	0.000399	0.00946	CbGeAlD
Gefitinib—Angiopathy—Hydroxyurea—head and neck cancer	0.000384	0.00612	CcSEcCtD
Gefitinib—CYP1A1—mouth—head and neck cancer	0.000376	0.0089	CbGeAlD
Gefitinib—Alopecia—Hydroxyurea—head and neck cancer	0.000374	0.00596	CcSEcCtD
Gefitinib—Anaemia—Vinblastine—head and neck cancer	0.000374	0.00595	CcSEcCtD
Gefitinib—STK10—thyroid gland—head and neck cancer	0.000371	0.00878	CbGeAlD
Gefitinib—Thrombophlebitis—Docetaxel—head and neck cancer	0.000368	0.00585	CcSEcCtD
Gefitinib—Malaise—Vinblastine—head and neck cancer	0.000365	0.00581	CcSEcCtD
Gefitinib—Hepatic failure—Docetaxel—head and neck cancer	0.000354	0.00564	CcSEcCtD
Gefitinib—Pneumonia—Fluorouracil—head and neck cancer	0.000342	0.00544	CcSEcCtD
Gefitinib—Anaemia—Hydroxyurea—head and neck cancer	0.000341	0.00543	CcSEcCtD
Gefitinib—Infestation NOS—Fluorouracil—head and neck cancer	0.00034	0.00541	CcSEcCtD
Gefitinib—Infestation—Fluorouracil—head and neck cancer	0.00034	0.00541	CcSEcCtD
Gefitinib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000336	0.00535	CcSEcCtD
Gefitinib—Dermatitis bullous—Docetaxel—head and neck cancer	0.000333	0.0053	CcSEcCtD
Gefitinib—Malaise—Hydroxyurea—head and neck cancer	0.000333	0.0053	CcSEcCtD
Gefitinib—Stomatitis—Fluorouracil—head and neck cancer	0.000331	0.00527	CcSEcCtD
Gefitinib—MAP2K5—thyroid gland—head and neck cancer	0.000331	0.00784	CbGeAlD
Gefitinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.00033	0.00526	CcSEcCtD
Gefitinib—STK10—head—head and neck cancer	0.000329	0.00779	CbGeAlD
Gefitinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000323	0.00515	CcSEcCtD
Gefitinib—EGFR—lymph node—head and neck cancer	0.000321	0.00761	CbGeAlD
Gefitinib—Epistaxis—Fluorouracil—head and neck cancer	0.00032	0.0051	CcSEcCtD
Gefitinib—Anorexia—Vinblastine—head and neck cancer	0.000315	0.00501	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000312	0.00497	CcSEcCtD
Gefitinib—CSNK1E—lymph node—head and neck cancer	0.000309	0.00731	CbGeAlD
Gefitinib—Haemoglobin—Fluorouracil—head and neck cancer	0.000307	0.00488	CcSEcCtD
Gefitinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000305	0.00486	CcSEcCtD
Gefitinib—IRAK4—lymph node—head and neck cancer	0.000304	0.0072	CbGeAlD
Gefitinib—Infection—Hydroxyurea—head and neck cancer	0.000299	0.00476	CcSEcCtD
Gefitinib—ERBB3—lymph node—head and neck cancer	0.000298	0.00706	CbGeAlD
Gefitinib—Dehydration—Docetaxel—head and neck cancer	0.000296	0.00471	CcSEcCtD
Gefitinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000295	0.0047	CcSEcCtD
Gefitinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000295	0.00469	CcSEcCtD
Gefitinib—MAP2K5—head—head and neck cancer	0.000294	0.00696	CbGeAlD
Gefitinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000292	0.00466	CcSEcCtD
Gefitinib—Dry skin—Docetaxel—head and neck cancer	0.000292	0.00465	CcSEcCtD
Gefitinib—Anorexia—Hydroxyurea—head and neck cancer	0.000287	0.00457	CcSEcCtD
Gefitinib—Decreased appetite—Vinblastine—head and neck cancer	0.000287	0.00457	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000287	0.00456	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000287	0.00456	CcSEcCtD
Gefitinib—MKNK2—lymph node—head and neck cancer	0.000283	0.00671	CbGeAlD
Gefitinib—IRAK1—lymph node—head and neck cancer	0.000283	0.00671	CbGeAlD
Gefitinib—Constipation—Vinblastine—head and neck cancer	0.000282	0.0045	CcSEcCtD
Gefitinib—Pain—Vinblastine—head and neck cancer	0.000282	0.0045	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000281	0.00447	CcSEcCtD
Gefitinib—MKNK1—lymph node—head and neck cancer	0.00028	0.00663	CbGeAlD
Gefitinib—ABCG2—parotid gland—head and neck cancer	0.000276	0.00653	CbGeAlD
Gefitinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000272	0.00434	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00027	0.0043	CcSEcCtD
Gefitinib—Alopecia—Fluorouracil—head and neck cancer	0.00027	0.00429	CcSEcCtD
Gefitinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000268	0.00427	CcSEcCtD
Gefitinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000264	0.00625	CbGeAlD
Gefitinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000262	0.00417	CcSEcCtD
Gefitinib—CYP1A1—parotid gland—head and neck cancer	0.000262	0.0062	CbGeAlD
Gefitinib—Abdominal pain—Vinblastine—head and neck cancer	0.000261	0.00416	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00026	0.00414	CcSEcCtD
Gefitinib—Fatigue—Hydroxyurea—head and neck cancer	0.00026	0.00413	CcSEcCtD
Gefitinib—Pain—Hydroxyurea—head and neck cancer	0.000257	0.0041	CcSEcCtD
Gefitinib—Constipation—Hydroxyurea—head and neck cancer	0.000257	0.0041	CcSEcCtD
Gefitinib—Weight decreased—Docetaxel—head and neck cancer	0.000249	0.00396	CcSEcCtD
Gefitinib—Pneumonia—Docetaxel—head and neck cancer	0.000247	0.00393	CcSEcCtD
Gefitinib—Anaemia—Fluorouracil—head and neck cancer	0.000245	0.00391	CcSEcCtD
Gefitinib—Infestation—Docetaxel—head and neck cancer	0.000245	0.00391	CcSEcCtD
Gefitinib—Infestation NOS—Docetaxel—head and neck cancer	0.000245	0.00391	CcSEcCtD
Gefitinib—Hypersensitivity—Vinblastine—head and neck cancer	0.000243	0.00387	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000243	0.00387	CcSEcCtD
Gefitinib—Stomatitis—Docetaxel—head and neck cancer	0.000239	0.00381	CcSEcCtD
Gefitinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000238	0.0038	CcSEcCtD
Gefitinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000238	0.00379	CcSEcCtD
Gefitinib—Asthenia—Vinblastine—head and neck cancer	0.000237	0.00377	CcSEcCtD
Gefitinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000232	0.00369	CcSEcCtD
Gefitinib—Epistaxis—Docetaxel—head and neck cancer	0.000231	0.00368	CcSEcCtD
Gefitinib—STK10—lymph node—head and neck cancer	0.00023	0.00546	CbGeAlD
Gefitinib—Diarrhoea—Vinblastine—head and neck cancer	0.000226	0.0036	CcSEcCtD
Gefitinib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000222	0.00353	CcSEcCtD
Gefitinib—Haemoglobin—Docetaxel—head and neck cancer	0.000221	0.00352	CcSEcCtD
Gefitinib—Hepatitis—Docetaxel—head and neck cancer	0.00022	0.00351	CcSEcCtD
Gefitinib—Haemorrhage—Docetaxel—head and neck cancer	0.00022	0.00351	CcSEcCtD
Gefitinib—CYP1A1—epithelium—head and neck cancer	0.000219	0.00518	CbGeAlD
Gefitinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000217	0.00346	CcSEcCtD
Gefitinib—Oedema peripheral—Docetaxel—head and neck cancer	0.000217	0.00345	CcSEcCtD
Gefitinib—Asthenia—Hydroxyurea—head and neck cancer	0.000216	0.00344	CcSEcCtD
Gefitinib—Urethral disorder—Docetaxel—head and neck cancer	0.000216	0.00344	CcSEcCtD
Gefitinib—Infection—Fluorouracil—head and neck cancer	0.000215	0.00343	CcSEcCtD
Gefitinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000213	0.00338	CcSEcCtD
Gefitinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000212	0.00338	CcSEcCtD
Gefitinib—Vomiting—Vinblastine—head and neck cancer	0.00021	0.00334	CcSEcCtD
Gefitinib—Erythema multiforme—Docetaxel—head and neck cancer	0.000208	0.00331	CcSEcCtD
Gefitinib—Anorexia—Fluorouracil—head and neck cancer	0.000207	0.00329	CcSEcCtD
Gefitinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000206	0.00328	CcSEcCtD
Gefitinib—Eye disorder—Docetaxel—head and neck cancer	0.000206	0.00328	CcSEcCtD
Gefitinib—MAP2K5—lymph node—head and neck cancer	0.000206	0.00487	CbGeAlD
Gefitinib—Cardiac disorder—Docetaxel—head and neck cancer	0.000204	0.00325	CcSEcCtD
Gefitinib—Hypotension—Fluorouracil—head and neck cancer	0.000202	0.00322	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—head and neck cancer	0.0002	0.00318	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000198	0.00316	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—head and neck cancer	0.000197	0.00313	CcSEcCtD
Gefitinib—Nausea—Vinblastine—head and neck cancer	0.000196	0.00312	CcSEcCtD
Gefitinib—Alopecia—Docetaxel—head and neck cancer	0.000195	0.0031	CcSEcCtD
Gefitinib—CYP1A1—trachea—head and neck cancer	0.000193	0.00458	CbGeAlD
Gefitinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000193	0.00308	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—head and neck cancer	0.000192	0.00305	CcSEcCtD
Gefitinib—Vomiting—Hydroxyurea—head and neck cancer	0.000191	0.00305	CcSEcCtD
Gefitinib—Rash—Hydroxyurea—head and neck cancer	0.00019	0.00302	CcSEcCtD
Gefitinib—Dermatitis—Hydroxyurea—head and neck cancer	0.00019	0.00302	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000188	0.003	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000187	0.00298	CcSEcCtD
Gefitinib—Pain—Fluorouracil—head and neck cancer	0.000185	0.00295	CcSEcCtD
Gefitinib—Nausea—Hydroxyurea—head and neck cancer	0.000179	0.00285	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—head and neck cancer	0.000177	0.00282	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—head and neck cancer	0.000172	0.00274	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000171	0.00273	CcSEcCtD
Gefitinib—Cough—Docetaxel—head and neck cancer	0.000167	0.00266	CcSEcCtD
Gefitinib—ORM1—lymph node—head and neck cancer	0.000167	0.00396	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000162	0.00258	CcSEcCtD
Gefitinib—ABCG2—thyroid gland—head and neck cancer	0.000161	0.00382	CbGeAlD
Gefitinib—Hypersensitivity—Fluorouracil—head and neck cancer	0.00016	0.00254	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—head and neck cancer	0.00016	0.00254	CcSEcCtD
Gefitinib—Infection—Docetaxel—head and neck cancer	0.000155	0.00247	CcSEcCtD
Gefitinib—Shock—Docetaxel—head and neck cancer	0.000154	0.00245	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000153	0.00244	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—head and neck cancer	0.000153	0.00244	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000153	0.00244	CcSEcCtD
Gefitinib—CYP1A1—thyroid gland—head and neck cancer	0.000153	0.00362	CbGeAlD
Gefitinib—Skin disorder—Docetaxel—head and neck cancer	0.000152	0.00242	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—head and neck cancer	0.000149	0.00237	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000148	0.00236	CcSEcCtD
Gefitinib—ALB—lymph node—head and neck cancer	0.000146	0.00347	CbGeAlD
Gefitinib—Hypotension—Docetaxel—head and neck cancer	0.000146	0.00233	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—head and neck cancer	0.000139	0.00222	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—head and neck cancer	0.000138	0.00219	CcSEcCtD
Gefitinib—Rash—Fluorouracil—head and neck cancer	0.000137	0.00218	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—head and neck cancer	0.000137	0.00217	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—head and neck cancer	0.000136	0.00217	CcSEcCtD
Gefitinib—CYP1A1—head—head and neck cancer	0.000136	0.00321	CbGeAlD
Gefitinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000135	0.00215	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—head and neck cancer	0.000135	0.00215	CcSEcCtD
Gefitinib—Pain—Docetaxel—head and neck cancer	0.000134	0.00213	CcSEcCtD
Gefitinib—Constipation—Docetaxel—head and neck cancer	0.000134	0.00213	CcSEcCtD
Gefitinib—Nausea—Fluorouracil—head and neck cancer	0.000129	0.00205	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000128	0.00204	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—head and neck cancer	0.000124	0.00197	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—head and neck cancer	0.000124	0.00197	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—head and neck cancer	0.000115	0.00184	CcSEcCtD
Gefitinib—ABCB1—epithelium—head and neck cancer	0.000114	0.00269	CbGeAlD
Gefitinib—Asthenia—Docetaxel—head and neck cancer	0.000112	0.00179	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—head and neck cancer	0.000111	0.00176	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—head and neck cancer	0.000107	0.0017	CcSEcCtD
Gefitinib—ABCB1—trachea—head and neck cancer	0.0001	0.00238	CbGeAlD
Gefitinib—ABCG2—lymph node—head and neck cancer	0.0001	0.00237	CbGeAlD
Gefitinib—Vomiting—Docetaxel—head and neck cancer	9.94e-05	0.00158	CcSEcCtD
Gefitinib—Rash—Docetaxel—head and neck cancer	9.86e-05	0.00157	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—head and neck cancer	9.85e-05	0.00157	CcSEcCtD
Gefitinib—CYP2D6—head—head and neck cancer	9.79e-05	0.00232	CbGeAlD
Gefitinib—CYP1A1—lymph node—head and neck cancer	9.5e-05	0.00225	CbGeAlD
Gefitinib—Nausea—Docetaxel—head and neck cancer	9.29e-05	0.00148	CcSEcCtD
Gefitinib—ABCB1—lymphoid tissue—head and neck cancer	8.74e-05	0.00207	CbGeAlD
Gefitinib—ABCB1—thyroid gland—head and neck cancer	7.94e-05	0.00188	CbGeAlD
Gefitinib—ABCB1—head—head and neck cancer	7.05e-05	0.00167	CbGeAlD
Gefitinib—ABCB1—lymph node—head and neck cancer	4.93e-05	0.00117	CbGeAlD
Gefitinib—CYP2C19—Metabolism—NAT2—head and neck cancer	1.06e-05	0.000115	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—head and neck cancer	1.04e-05	0.000113	CbGpPWpGaD
Gefitinib—MKNK1—Disease—AKT1—head and neck cancer	1.04e-05	0.000113	CbGpPWpGaD
Gefitinib—ALB—Metabolism—DPYD—head and neck cancer	1.03e-05	0.000112	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NAT2—head and neck cancer	1.03e-05	0.000112	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—STAT3—head and neck cancer	1.03e-05	0.000112	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MAPK1—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PIK3CA—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MAPK1—head and neck cancer	1.02e-05	0.00011	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCND1—head and neck cancer	1.01e-05	0.00011	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.01e-05	0.00011	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PIK3CA—head and neck cancer	9.86e-06	0.000107	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MAPK3—head and neck cancer	9.86e-06	0.000107	CbGpPWpGaD
Gefitinib—ALB—Metabolism—YAP1—head and neck cancer	9.8e-06	0.000106	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTEN—head and neck cancer	9.79e-06	0.000106	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NAT2—head and neck cancer	9.73e-06	0.000106	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	9.66e-06	0.000105	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NAT2—head and neck cancer	9.64e-06	0.000105	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PTEN—head and neck cancer	9.61e-06	0.000104	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOTCH1—head and neck cancer	9.59e-06	0.000104	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—TYMS—head and neck cancer	9.54e-06	0.000104	CbGpPWpGaD
Gefitinib—ERBB3—Disease—STAT3—head and neck cancer	9.53e-06	0.000103	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	9.51e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—head and neck cancer	9.51e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—head and neck cancer	9.45e-06	0.000103	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTM1—head and neck cancer	9.43e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MAPK3—head and neck cancer	9.42e-06	0.000102	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MAPK1—head and neck cancer	9.38e-06	0.000102	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—head and neck cancer	9.38e-06	0.000102	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—DPYD—head and neck cancer	9.28e-06	0.000101	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	9.2e-06	9.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOTCH1—head and neck cancer	9.16e-06	9.95e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—head and neck cancer	9.13e-06	9.91e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MAPK3—head and neck cancer	9.1e-06	9.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—DPYD—head and neck cancer	9.05e-06	9.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CASP8—head and neck cancer	9.04e-06	9.81e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GPX1—head and neck cancer	9.03e-06	9.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MAPK1—head and neck cancer	8.97e-06	9.74e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP1A1—head and neck cancer	8.94e-06	9.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDH1—head and neck cancer	8.93e-06	9.7e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PIK3CA—head and neck cancer	8.88e-06	9.65e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—head and neck cancer	8.84e-06	9.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—YAP1—head and neck cancer	8.8e-06	9.56e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STAT3—head and neck cancer	8.76e-06	9.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MAPK1—head and neck cancer	8.66e-06	9.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—head and neck cancer	8.66e-06	9.41e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—head and neck cancer	8.59e-06	9.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—STAT3—head and neck cancer	8.59e-06	9.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—YAP1—head and neck cancer	8.59e-06	9.33e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—DPYD—head and neck cancer	8.53e-06	9.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—DPYD—head and neck cancer	8.46e-06	9.19e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MAPK3—head and neck cancer	8.37e-06	9.09e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—head and neck cancer	8.34e-06	9.06e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—head and neck cancer	8.23e-06	8.93e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—head and neck cancer	8.22e-06	8.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MAPK3—head and neck cancer	8.21e-06	8.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—head and neck cancer	8.15e-06	8.85e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PIK3CA—head and neck cancer	8.14e-06	8.84e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—YAP1—head and neck cancer	8.1e-06	8.79e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.08e-06	8.78e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—head and neck cancer	8.06e-06	8.75e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—YAP1—head and neck cancer	8.03e-06	8.72e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—head and neck cancer	8.02e-06	8.71e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MAPK1—head and neck cancer	7.96e-06	8.65e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—head and neck cancer	7.96e-06	8.64e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—head and neck cancer	7.93e-06	8.61e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	7.89e-06	8.57e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MAPK1—head and neck cancer	7.81e-06	8.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—head and neck cancer	7.81e-06	8.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PIK3CA—head and neck cancer	7.78e-06	8.45e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	7.77e-06	8.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL2—head and neck cancer	7.75e-06	8.42e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTEN—head and neck cancer	7.74e-06	8.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—head and neck cancer	7.73e-06	8.4e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—head and neck cancer	7.53e-06	8.18e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PIK3CA—head and neck cancer	7.52e-06	8.16e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—head and neck cancer	7.5e-06	8.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—head and neck cancer	7.47e-06	8.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PIK3CA—head and neck cancer	7.47e-06	8.12e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTEN—head and neck cancer	7.46e-06	8.1e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.37e-06	8e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—head and neck cancer	7.26e-06	7.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—head and neck cancer	7.2e-06	7.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—head and neck cancer	7.2e-06	7.82e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.05e-06	7.66e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—head and neck cancer	6.99e-06	7.59e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—head and neck cancer	6.95e-06	7.55e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—head and neck cancer	6.92e-06	7.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—head and neck cancer	6.91e-06	7.51e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—head and neck cancer	6.91e-06	7.5e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—head and neck cancer	6.84e-06	7.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—head and neck cancer	6.83e-06	7.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—head and neck cancer	6.8e-06	7.39e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—head and neck cancer	6.78e-06	7.36e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—head and neck cancer	6.76e-06	7.34e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—head and neck cancer	6.74e-06	7.32e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—head and neck cancer	6.68e-06	7.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—head and neck cancer	6.67e-06	7.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—head and neck cancer	6.65e-06	7.22e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.61e-06	7.18e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK3—head and neck cancer	6.61e-06	7.18e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—head and neck cancer	6.6e-06	7.17e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—head and neck cancer	6.47e-06	7.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—head and neck cancer	6.46e-06	7.02e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—head and neck cancer	6.44e-06	6.99e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.42e-06	6.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—head and neck cancer	6.42e-06	6.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—head and neck cancer	6.41e-06	6.97e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP1A1—head and neck cancer	6.41e-06	6.96e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—head and neck cancer	6.39e-06	6.94e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—head and neck cancer	6.38e-06	6.93e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK3—head and neck cancer	6.37e-06	6.92e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—head and neck cancer	6.37e-06	6.92e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NAT2—head and neck cancer	6.36e-06	6.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—head and neck cancer	6.36e-06	6.9e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK1—head and neck cancer	6.29e-06	6.83e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—head and neck cancer	6.29e-06	6.83e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—head and neck cancer	6.27e-06	6.81e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—head and neck cancer	6.21e-06	6.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—head and neck cancer	6.14e-06	6.67e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—head and neck cancer	6.11e-06	6.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—head and neck cancer	6.1e-06	6.63e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—head and neck cancer	6.07e-06	6.59e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—head and neck cancer	6.06e-06	6.59e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	6.03e-06	6.55e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—head and neck cancer	6.03e-06	6.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—head and neck cancer	6.01e-06	6.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—head and neck cancer	5.93e-06	6.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—head and neck cancer	5.89e-06	6.39e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—head and neck cancer	5.82e-06	6.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.77e-06	6.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—head and neck cancer	5.75e-06	6.24e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—head and neck cancer	5.74e-06	6.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—head and neck cancer	5.72e-06	6.21e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—head and neck cancer	5.64e-06	6.13e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—head and neck cancer	5.61e-06	6.09e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DPYD—head and neck cancer	5.58e-06	6.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—head and neck cancer	5.57e-06	6.05e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—head and neck cancer	5.55e-06	6.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—head and neck cancer	5.54e-06	6.01e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP1A1—head and neck cancer	5.52e-06	5.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—head and neck cancer	5.49e-06	5.96e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	5.46e-06	5.93e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—head and neck cancer	5.32e-06	5.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—head and neck cancer	5.31e-06	5.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—head and neck cancer	5.3e-06	5.76e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—YAP1—head and neck cancer	5.29e-06	5.75e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—head and neck cancer	5.29e-06	5.74e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	5.28e-06	5.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—head and neck cancer	5.26e-06	5.72e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	5.26e-06	5.71e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—head and neck cancer	5.22e-06	5.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—head and neck cancer	5.22e-06	5.67e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—head and neck cancer	5.16e-06	5.6e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—head and neck cancer	5.1e-06	5.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—head and neck cancer	5.09e-06	5.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—head and neck cancer	5.07e-06	5.5e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	5.05e-06	5.49e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—head and neck cancer	5.05e-06	5.48e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—head and neck cancer	5.05e-06	5.48e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—head and neck cancer	5e-06	5.43e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—head and neck cancer	4.98e-06	5.41e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.97e-06	5.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—head and neck cancer	4.96e-06	5.39e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP1A1—head and neck cancer	4.95e-06	5.38e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—head and neck cancer	4.88e-06	5.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—head and neck cancer	4.87e-06	5.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—head and neck cancer	4.86e-06	5.28e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	4.83e-06	5.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—head and neck cancer	4.82e-06	5.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—head and neck cancer	4.82e-06	5.23e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—head and neck cancer	4.82e-06	5.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—head and neck cancer	4.81e-06	5.22e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—head and neck cancer	4.76e-06	5.17e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—head and neck cancer	4.64e-06	5.04e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—head and neck cancer	4.61e-06	5e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—head and neck cancer	4.6e-06	5e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—head and neck cancer	4.59e-06	4.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—head and neck cancer	4.56e-06	4.95e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	4.56e-06	4.95e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.53e-06	4.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—head and neck cancer	4.53e-06	4.92e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1A1—head and neck cancer	4.52e-06	4.9e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	4.46e-06	4.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—head and neck cancer	4.41e-06	4.79e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—head and neck cancer	4.38e-06	4.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—head and neck cancer	4.3e-06	4.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—head and neck cancer	4.3e-06	4.67e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—head and neck cancer	4.24e-06	4.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—head and neck cancer	4.19e-06	4.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—head and neck cancer	4.18e-06	4.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—head and neck cancer	4.15e-06	4.51e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.07e-06	4.42e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—head and neck cancer	4.07e-06	4.42e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—head and neck cancer	4.05e-06	4.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—head and neck cancer	4.05e-06	4.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—head and neck cancer	3.87e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—head and neck cancer	3.81e-06	4.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—head and neck cancer	3.75e-06	4.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—head and neck cancer	3.71e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.71e-06	4.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—head and neck cancer	3.7e-06	4.02e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—head and neck cancer	3.6e-06	3.91e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—head and neck cancer	3.58e-06	3.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—head and neck cancer	3.55e-06	3.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—head and neck cancer	3.42e-06	3.71e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—head and neck cancer	3.38e-06	3.67e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—head and neck cancer	3.32e-06	3.61e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—head and neck cancer	3.28e-06	3.56e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	3.27e-06	3.55e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—head and neck cancer	3.18e-06	3.45e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.14e-06	3.41e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—head and neck cancer	3.14e-06	3.41e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—head and neck cancer	3.01e-06	3.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.98e-06	3.23e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—head and neck cancer	2.95e-06	3.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—head and neck cancer	2.93e-06	3.18e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—head and neck cancer	2.87e-06	3.12e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—head and neck cancer	2.86e-06	3.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—head and neck cancer	2.83e-06	3.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—head and neck cancer	2.71e-06	2.94e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—head and neck cancer	2.71e-06	2.94e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—head and neck cancer	2.69e-06	2.92e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—head and neck cancer	2.67e-06	2.9e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—head and neck cancer	2.57e-06	2.79e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—head and neck cancer	2.51e-06	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—head and neck cancer	2.39e-06	2.6e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—head and neck cancer	2.36e-06	2.57e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	2.34e-06	2.55e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—head and neck cancer	2.34e-06	2.54e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—head and neck cancer	2.21e-06	2.41e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—head and neck cancer	2.02e-06	2.19e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—head and neck cancer	1.91e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—head and neck cancer	1.81e-06	1.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—head and neck cancer	1.81e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.77e-06	1.92e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.77e-06	1.92e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.67e-06	1.81e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—head and neck cancer	1.65e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—head and neck cancer	1.65e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—head and neck cancer	1.54e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—head and neck cancer	1.48e-06	1.61e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—head and neck cancer	1.44e-06	1.57e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—head and neck cancer	1.36e-06	1.48e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—head and neck cancer	1.35e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.09e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—head and neck cancer	8.9e-07	9.67e-06	CbGpPWpGaD
